BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34686508)

  • 1. UDP-Glucose Ceramide Glycosyltransferase Contributes to the Proliferation and Glycolysis of Cervical Cancer Cells by Regulating the PI3K/AKT Pathway.
    Zhang F; Zhang H
    Ann Clin Lab Sci; 2021 Sep; 51(5):663-669. PubMed ID: 34686508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Period circadian regulator 2 suppresses drug resistance to cisplatin by PI3K/AKT pathway and improves chronochemotherapeutic efficacy in cervical cancer.
    Wang Z; Li F; He S; Zhao L; Wang F
    Gene; 2022 Jan; 809():146003. PubMed ID: 34648915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UDP-glucose ceramide glucosyltransferase activates AKT, promoted proliferation, and doxorubicin resistance in breast cancer cells.
    Wegner MS; Schömel N; Gruber L; Örtel SB; Kjellberg MA; Mattjus P; Kurz J; Trautmann S; Peng B; Wegner M; Kaulich M; Ahrends R; Geisslinger G; Grösch S
    Cell Mol Life Sci; 2018 Sep; 75(18):3393-3410. PubMed ID: 29549423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSAT1 Upregulation Contributes to Cell Growth and Cisplatin Resistance in Cervical Cancer Cells via Regulating PI3K/AKT Signaling Pathway.
    Duan W; Liu X
    Ann Clin Lab Sci; 2020 Jul; 50(4):512-518. PubMed ID: 32826249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALC1 knockdown enhances cisplatin cytotoxicity of esophageal squamous cell carcinoma cells by inhibition of glycolysis through PI3K/Akt pathway.
    Li F; Zhang Z; Wang P; Wen P; Xu Q; Wang Y; Pan P; Ma L
    Life Sci; 2019 Sep; 232():116679. PubMed ID: 31340168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-induced CNPY2 upregulation promotes glycolysis in cervical cancer through activation of AKT pathway.
    Tian T; Dong Y; Zhu Y; Chen Y; Li X; Kuang Q; Liu X; Li P; Li J; Zhou L
    Biochem Biophys Res Commun; 2021 Apr; 551():63-70. PubMed ID: 33721832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
    Su J; Zhang F; Li X; Liu Z
    Biochem Biophys Res Commun; 2019 Jun; 514(2):510-517. PubMed ID: 31056260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UBE2T promotes proliferation, invasion and glycolysis of breast cancer cells by regualting the PI3K/AKT signaling pathway.
    Qiao L; Dong C; Ma B
    J Recept Signal Transduct Res; 2022 Apr; 42(2):151-159. PubMed ID: 33435787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased ceramide production sensitizes breast cancer cell response to chemotherapy.
    Che J; Huang Y; Xu C; Zhang P
    Cancer Chemother Pharmacol; 2017 May; 79(5):933-941. PubMed ID: 28357533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transglutaminase 3 suppresses proliferation and cisplatin resistance of cervical cancer cells by inactivation of the PI3K/AKT pathway.
    Chen R; Fang T; Liu N; Shi X; Wang J; Yu H
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Apr; 397(4):2269-2280. PubMed ID: 37812238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of miR-202-5p silencing PIK3CA gene expression on proliferation, invasion, and epithelial-mesenchymal transition of cervical cancer SiHa cells through inhibiting PI3K/Akt/mTOR signaling pathway activation.
    Zheng Y; Xie L; Xu S; Yan W; Zhang H; Meng Y; Liu J; Wei X
    Mol Cell Biochem; 2021 Nov; 476(11):4031-4044. PubMed ID: 34244973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of hnRNP A2/B1 inhibits cell proliferation, invasion and cell cycle triggering apoptosis in cervical cancer via PI3K/AKT signaling pathway.
    Shi X; Ran L; Liu Y; Zhong SH; Zhou PP; Liao MX; Fang W
    Oncol Rep; 2018 Mar; 39(3):939-950. PubMed ID: 29328485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The UDP-glucose ceramide glycosyltransferase (UGCG) and the link to multidrug resistance protein 1 (MDR1).
    Wegner MS; Gruber L; Mattjus P; Geisslinger G; Grösch S
    BMC Cancer; 2018 Feb; 18(1):153. PubMed ID: 29409484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-125 inhibited cervical cancer progression by regulating VEGF and PI3K/AKT signaling pathway.
    Fu K; Zhang L; Liu R; Shi Q; Li X; Wang M
    World J Surg Oncol; 2020 May; 18(1):115. PubMed ID: 32473637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
    Gao BB; Wang SX
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Li YJ; Wang Y; Wang YY
    J Cell Physiol; 2019 Jun; 234(6):9577-9591. PubMed ID: 30480801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin αvβ3 and activating FAK/PI3K/AKT signaling.
    Luo J; Yao JF; Deng XF; Zheng XD; Jia M; Wang YQ; Huang Y; Zhu JH
    J Exp Clin Cancer Res; 2018 Feb; 37(1):23. PubMed ID: 29426357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. microRNA-383 suppresses the PI3K-AKT-MTOR signaling pathway to inhibit development of cervical cancer via down-regulating PARP2.
    Teng P; Jiao Y; Hao M; Tang X
    J Cell Biochem; 2018 Jul; 119(7):5243-5252. PubMed ID: 29236322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyanidin-3-O-glucoside and cisplatin inhibit proliferation and downregulate the PI3K/AKT/mTOR pathway in cervical cancer cells.
    Li X; Zhao J; Yan T; Mu J; Lin Y; Chen J; Deng H; Meng X
    J Food Sci; 2021 Jun; 86(6):2700-2712. PubMed ID: 33908630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.